达安基因2025年度利润分配公告详解

广州达安基因股份有限公司（证券代码：002030）近日发布了关于2025年度利润分配方案的公告，内容涉及利润分配决策、分红政策、以及可能影响股东权益的重要信息。本文将为投资者详细解读公告内容，并分析其对公司股票价格的潜在影响。

公告要点概述

• 2025年度利润分配方案：公司拟不派发现金红利、不送红股，也不以资本公积转增股本。
• 公司2025年度业绩：合并报表实现归属于上市公司股东的净利润为负值，亏损高达-744,378,901.74元；母公司净利润也为负值，亏损-674,365,843.34元。
• 累计未分配利润：年末合并报表未分配利润为3,867,020,079.05元，母公司未分配利润为4,103,710,076.31元。
• 董事会决议：2026年4月24日的董事会会议11票全票通过该利润分配议案，尚需提交股东大会审议。

股东须知及对股价的潜在影响

• 连续亏损：公司2025年度及2024年度均为亏损状态，且2023年度仅实现微薄盈利。这反映公司经营压力较大，可能影响市场对公司未来盈利能力的预期。
• 无现金分红：公司2023-2025年度累计现金分红金额仅为21,051,690.48元，2024及2025年度均未分红。分红政策的改变可能影响部分投资者信心，尤其是以分红为投资目标的股东。
• 不触及风险警示：公告明确公司未触及深圳证券交易所股票上市规则第9.8.1条相关风险警示情形，说明公司短期内不会因分红政策或亏损而被实施风险警示。
• 利润分配政策合理性：公司解释利润分配方案已综合考虑行业现状、发展战略、经营情况及后续资金需求，符合法律法规及公司章程要求。

投资者需要关注的其他细节

• 现金分红与回购情况：近三年（2023-2025）累计现金分红21,051,690.48元，回购注销金额为零。
• 平均净利润：近三年平均净利润为-521,629,714.14元，显示公司持续亏损。
• 后续决策流程：此次利润分配议案需提交2025年度股东大会审议，并最终决定是否实施。

对股价的潜在影响分析

本公告揭示了公司连续亏损、现金分红缺失以及未来发展战略的调整。对于市场而言，持续亏损和不分红通常会对股价产生负面影响，尤其是对于偏好分红的投资者。此外，公告虽未触及风险警示，但公司盈利能力和分红政策的变化仍需投资者高度关注。

备查文件

• 第九届董事会第二次会议决议

综上所述，本公告包含多项对股东及投资者具有重要影响的信息，可能引发市场对达安基因业绩与分红政策的关注，进而影响公司股价。

免责声明：本文仅为信息解读与分析，不构成任何投资建议。投资者应结合自身情况及其他公开信息，审慎决策。公司公告内容如有变动，请以官方公告为准。

Detailed Analysis of Daan Gene’s 2025 Profit Distribution Announcement

Guangzhou Daan Gene Co., Ltd. (Stock Code: 002030) recently released its 2025 profit distribution plan, including key decisions on dividend policy and information critical to shareholders. This article provides a thorough analysis for investors, focusing on details that may affect share value.

Summary of Key Points

• 2025 Profit Distribution Plan: The company proposes not to pay cash dividends, issue bonus shares, or convert capital reserves into share capital.
• 2025 Performance: Consolidated net profit attributable to shareholders was a loss of RMB -744,378,901.74; the parent company also recorded a loss of RMB -674,365,843.34.
• Accumulated Undistributed Profit: Year-end consolidated undistributed profit amounted to RMB 3,867,020,079.05; parent company undistributed profit was RMB 4,103,710,076.31.
• Board Decision: On April 24, 2026, the board unanimously passed the profit distribution proposal, pending shareholder approval at the annual meeting.

Shareholder Concerns & Price Sensitivity

• Continued Losses: The company recorded losses in both 2025 and 2024, with only a small profit in 2023, indicating ongoing business challenges that may affect market confidence.
• No Cash Dividend: Cumulative cash dividends over 2023-2025 were only RMB 21,051,690.48, with none paid in 2024 or 2025. This change in dividend policy may impact investor sentiment, especially for those seeking regular dividends.
• No Risk Warning Triggered: The announcement clarifies that the company does not trigger any risk warnings under Shenzhen Stock Exchange rules, suggesting no immediate regulatory risk.
• Distribution Policy Justification: The company states that its decision is based on industry conditions, strategic development, operational status, and future capital needs, in line with laws and the company’s articles of association.

Additional Details for Investors

• Dividend and Buyback: Over the past three years, cash dividends totaled RMB 21,051,690.48, with no buybacks.
• Average Net Profit: The three-year average net profit is RMB -521,629,714.14, indicating sustained losses.
• Decision Process: The proposal must be approved at the 2025 annual shareholders meeting for final implementation.

Potential Impact on Share Price

The announcement reveals ongoing losses, absence of cash dividends, and strategic adjustments. For the market, sustained losses and lack of dividends may negatively impact share price, especially among dividend-focused investors. While no regulatory risk is triggered, changes in profitability and dividend policy are noteworthy for investors.

Reference Documents

• Board resolution of the ninth session, second meeting

In summary, this announcement contains information of significant importance to shareholders and investors, likely to attract attention to Daan Gene’s performance and dividend policy, and may impact share price.

Disclaimer: This article is for information and analysis only, and does not constitute investment advice. Investors should make prudent decisions based on their own circumstances and other public information. Please refer to official company announcements for any updates.

View 达安基因 Historical chart here